Neonatal Drug Therapy Manual


Disclaimer: Official controlled document is the CHEO and Ottawa Hospital online copy. It is the responsibility of user to ensure that any paper copy version is the same as the online version before use.

Alternate Name(s): 
Original Date: 
August 2009
Revised Date: 
February 2015
  • Treatment of neonatal hypertension
  • IV direct: over 3 - 5 minutes
    • infusion rate not to exceed 5 mg/min or 0.2 mg/kg/min
  • IV intermittent infusion: over 15 minutes
  • PO
  • IV: initial: 0.1 - 0.2 mg/kg/dose every 4 - 6 hours up to a max of 0.6 mg/kg/dose
  • PO: 0.2 - 1.25 mg/kg/dose every 6 hours

Dose adjustments required in renal impairment. Refer to available references or clinical pharmacist for dosage adjustment

Side Effects: 
  • CVS: hypotension, tachycardia
  • Dermatologic: rash
  • GI: nausea, vomiting, diarrhea
  • Miscellaneous: SLE-like syndrome
Parameters to Monitor: 
  • HR
  • BP
Reconstitution and Stability: 

IV direct:

  • Hydralazine 20 mg/mL
    • Take 1 mL (20 mg) and add to 19 mL of 0.9% NaCl
    • Final concentration: 1 mg/mL

- Solutions Compatible: D10W, 0.9% NaCl, dextrose-saline combinations


- Y-site Compatible: dobutamine, heparin, KCl (up to 40 mEq/L) if mixed with 0.9% NaCl


- Incompatible: ampicillin, furosemide, D5W, hydrocortisone, phenobarbital


- Taketomo CK, Hodding JH, Kraus DM. Pediatric Dosage Handbook 20th Edition. Hudson: Lexi-Comp Inc.; 2013

-Lau E. (Editor). Drug Handbook and Formulary- The Hospital for Sick Children. Toronto: 2013-2014

-Trissel LA. Handbook on Injectable Drugs. 16th Edition. Bethesda: American Society of Health-System Pharmacists; 2003-2005.

-The Childrens Hospital of Eastern Ontario Parenteral Drug Manual. Department of Pharmacy 2009

The information contained on this website is provided for informational purposes only, as a guide to assist physicians, nurses and other healthcare providers in deciding on the appropriate care required for a particular patient. At all times, physicians, nurses and other healthcare providers must exercise their independent clinical judgment, based on their knowledge, training and experience, taking into account the specific facts and circumstances of each patient, when deciding on the appropriate course of investigation and/or treatment to recommend in a particular clinical situation.

CHEO has made every effort to ensure that the information contained on this website is as current and accurate as possible. However, changes can occur due to ongoing research and the constant influx of new information. Where possible, hospitals and healthcare practitioners should verify the information before acting on it.

Reliance on any information in this website is at the user's own risk. CHEO is not responsible or liable for any harm, loss or other consequences from the use or misuse of the information on this website.